Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.3.1.900
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities:    
Net loss $ (1,927,000) $ (1,304,000)
Less: (loss) income on discontinued operations, net of taxes 1,864,000 (1,688,000)
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest (63,000) (2,992,000)
Adjustments to reconcile net income (loss) from continuing operations to cash used in operating activities:    
Depreciation and amortization 3,717,000 4,240,000
Amortization of debt discount 87,000 86,000
Deferred tax expense 418,000 539,000
(Recovery of) provision for bad debt reserves $ (433,000) 291,000
Goodwill, Impairment Loss 380,000
Gain on disposal of plant, property and equipment $ (80,000) (41,000)
Loss on sale of SYA subsidiary (see Note 8) 53,000
Issuance of common stock for services $ 282,000 270,000
Stock-based compensation 92,000 34,000
Changes in operating assets and liabilities of continuing operations:    
Accounts receivable (968,000) (713,000)
Unbilled receivables 2,174,000 (2,606,000)
Prepaid expenses, inventories and other assets 135,000 1,149,000
Accounts payable, accrued expenses and unearned revenue (3,657,000) (29,000)
Cash provided by continuing operations 1,704,000 661,000
Cash used in discontinued operations (2,862,000) (2,093,000)
Cash used in operating activities (1,158,000) (1,432,000)
Cash flows from investing activities:    
Purchases of property and equipment (623,000) (464,000)
Proceeds from sale of plant, property and equipment 127,000 133,000
Proceeds from sale of SYA subsidiary (see Note 8) 50,000 1,214,000
Payments to finite risk sinking fund (46,000) (27,000)
Cash (used in) provided by investing activities of continuing operations $ (492,000) 856,000
Proceeds from property insurance claims of discontinued operations (see Note 8) 5,727,000
Cash (used in) provided by investing activities $ (492,000) 6,583,000
Cash flows from financing activities:    
Borrowing on revolving credit 67,614,000 66,644,000
Repayments of revolving credit (65,265,000) (66,644,000)
Principal repayments of long term debt (2,320,000) (2,463,000)
Principal repayments of long term debt - related party (1,500,000) (500,000)
Proceeds from issuance of common stock 10,000 7,000
Issuance of stock - Perma-Fix Medical S.A., net of expenses of $29 and $242, respectively 971,000 1,187,000
Cash used in financing activities of continuing operations $ (490,000) (1,769,000)
Principal repayment of long-term debt for discontinued operations (35,000)
Cash used in financing activities $ (490,000) $ (1,804,000)
Effect of exchange rate changes on cash (105,000)
(Decrease) increase in cash (2,245,000) $ 3,347,000
Cash at beginning of period 3,680,000 333,000
Cash at end of period 1,435,000 3,680,000
Supplemental disclosure:    
Interest paid 903,000 607,000
Income taxes paid 116,000 $ 41,000
Proceeds from stock subscription for Perma-Fix Medical S.A. held in escrow $ 67,000